Testing an oral GLP-1/2 capsule in healthy volunteers
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests a new oral capsule that delivers a medicine called PG-102, which is a dual GLP-1/2 agonist (similar to drugs used for diabetes and weight loss). It is for healthy volunteers to see how the body handles the medicine. The study has two parts: one for people with a lower BMI and one for people with a higher BMI (over 30).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a body mass index (BMI) that fits one of the study parts: 19–32 (Part A) or above 30 (Part B).
- You are in good general health, with no major medical conditions like heart disease, diabetes, or liver problems.
- You have not taken any GLP-1 or GLP-2 medications (like Ozempic or Wegovy) in the last 3 months.
- You have not had weight loss surgery or a significant weight loss (more than 5%) in the last 2 months.
- You are willing to avoid pregnancy, donate sperm, or blood donation during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental medication that may help with weight loss. It aims to see how safe the drug is and how the body responds, possibly leading to a new treatment option for obesity.
This study tests a new medicine (NNC6989-0001) for people who are overweight or have obesity. It checks if the medicine is safe and how the body handles it. If eligible, you would receive the study drug and be monitored closely.
This study tests a new oral medication called ACCG-2671 to see how safe it is and how your body handles it. It's an early-stage trial, so the main focus is on safety and tolerability. The study has different parts: one for people with normal weight and one for people with higher weight who are already taking a GLP-1 injection for weight loss.
This study tests how different amounts of the study medicine PF-08642534 are tolerated and how they work in the body of people with obesity. It aims to find a safe dose for future studies.
This study is for people who have lost weight using GLP-1 injections (like semaglutide or tirzepatide) and are thinking about stopping them. It tests whether switching to an oral weight-loss medication can help you keep the weight off.
This study tests an experimental drug called IBI3042 in healthy people who are normal weight, overweight, or obese. It is an early-stage trial looking at how safe and tolerable the drug is, and how it affects the body, which could eventually lead to a treatment for weight loss.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.